Tysabri Re-Entry Hinges On Effective Risk Management: Diagnostics May Be Key

Any risk management program tied to the market re-entry of Biogen Idec/Elan's Tysabri would likely include diagnostic procedures to test for early signs of progressive multifocal leukoencephalopathy